Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
暂无分享,去创建一个
Tsuyoshi Saito | Kenichi Inoue | H. Yamada | K. Okubo | J. Ninomiya | T. Nakakuma | K. Kimizuka | T. Higuchi